Literature DB >> 884690

Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.

L B Mellett.   

Abstract

The blood-brain barrier is not as rigid or as formidable as once believed. When experimental tumors of the central nervous system (CNS) and tumors of non-CNS origin are implanted intracerebrally (ic), they will grow and kill the host. It was once thought that only a few select agents, such as the nitrosoureas, were capable of crossing the blood-brain barrier and inhibiting tumor growth. There are now considerable data available which indicate that a variety of agents such as cytosine arabinoside, methotrexate, 6-mercaptopurine, 5-fluorouracil, procarbazine, melphalan, and cyclophosphamide, as well as the nitrosoureas, may significantly influence the growth rate of experimentally implanted ic tumors. A number of physicochemical factors may influence the penetration of the blood-brain barrier. These include pKa values, log-P values, and molecular size. Brain-level measurements indicate that most drugs have some accessibility to the CNS. Maximal effects against sensitive, ic implanted tumors are attained through maximal scheduling. Effective drug combinations should be sought to further enhance antitumor effects in the CNS.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 884690

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  18 in total

Review 1.  Current options for the treatment of neoplastic meningitis.

Authors:  Ilkcan Cokgor; Allan H Friedman; Henry S Friedman
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

2.  Neurotoxicity and dermatotoxicity of cyanomorpholinyl adriamycin.

Authors:  S C Cramer; R H Rhodes; E M Acton; Z A Tökés
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Time-dependence and selectivity of immunosuppressive agents.

Authors:  M C Berenbaum
Journal:  Immunology       Date:  1979-02       Impact factor: 7.397

4.  Prospective randomized cooperative medulloblastoma trial (MED 84) of the International Society of Paediatric Oncology (SIOP) and of the (German) Society of Paediatric Oncology (GPO).

Authors:  M K Neidhardt; C C Bailey
Journal:  Childs Nerv Syst       Date:  1987       Impact factor: 1.475

5.  6-Thioguanine: high-dose 2-H infusions in goats.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; M B van Leeuwen; J M van Baal; G A de Vaan
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

Review 6.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.

Authors:  L G Feun; N Savaraj; K Lu; Z Guo; L G Raulston; R S Benjamin; W S Fields; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).

Authors:  N Savaraj; K Lu; L G Feun; M E Leavens; D Stewart; M A Burgess; R S Benjamin; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

9.  A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.

Authors:  L G Feun; W K Yung; M E Leavens; M A Burgess; E A Obbens; A Y Bedikian; N Savaraj; D J Stewart; R S Benjamin; W S Fields
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

10.  6-mercaptopurine: high-dose 24-h infusions in goats.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; J M van Baal; M B van Leeuwen; G A de Vaan
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.